NCT02150876

SWiss Evaluation of Bioabsorbable Polymer-coated Everolimus-eluting Coronary sTent

SWiss Evaluation of Bioabsorbable Polymer-coated Everolimus-eluting Coronary sTent The SWEET Registry

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 1,000 (actual)
• Sponsor: University of Freiburg · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Bioresorbable polymer drug eluting stents (DES) are an indisputable improvement over first-generation DES with promising results on long-term adverse events. But the thicker polymer and/or strut may hinder its deliverability. Complex procedures challenge stent deliverability and stent delivery failure impacts clinical prognosis. This registry aimed to assess the immediate performance of the third-generation Synergy everolimus-eluting stent (sEES) and its 12-month clinical follow-up in an all-comer population.

Detailed description

All consecutive patients treated with the SYNERGY stent at our institutions were prospectively included in the SWEET registry. Baseline and procedural characteristics were collected at index procedure. Clinical follow-up was performed at 1 month and 1 year by clinic visit or follow-up call. The study end point was a composite of cardiac death (CD), myocardial infarction (MI) and target lesion revascularization (TLR) at 1 year.

Conditions

• Coronary Artery Disease

Timeline

• Start date: 2014-06-01
• Primary completion: 2014-09-01
• Completion: 2014-09-01
• First posted: 2014-05-30
• Last updated: 2015-12-03

Locations

1 site across 1 country: Switzerland